Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of…

By Marc A. F. De Hert, J. Dekker, David R. Wood, K. Kahl, R. Holt, Hans-Jürgen Möller. European psychiatry, 2009

892 citations recorded by the source corpus.

Abstract People with severe mental illnesses, such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life expectancy compared to the general population. The excess cardiovascular mortality associated with schizophrenia and bipolar disorder is attributed in part to an increased risk of the modifiable coronary heart disease risk factors; obesity, smoking, diabetes, hypertension and dyslipidaemia. Antipsychotic medication and possibly other psychotropic medication like antidepressants can induce weight gain or worsen other metabolic cardiovascular risk factors. Patients may have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population. The European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) published this statement with the aim of improving the care of patients suffering from severe mental illness. The intention is to initiate cooperation and shared care between the different healthcare professionals and to increase the awareness of psychiatrists and primary care physicians caring for patients with severe mental illness to screen and treat cardiovascular risk factors and diabetes.

Subfields: Endocrinology, Diabetes and Metabolism, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/26ed70a8b5c5bf983da05296682cbee5b9cfe483

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. (2013, background): “In recent years, it has become apparent that in patients with schizophrenia particular antipsychotic agents (AP) can have a negative impact on some of themodifiableMetS risk factors.(4,5) The differential effects of various AP on weight arewell described, with clozapine and olanzapine associated wit”
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011, background): “The aetiology of this excess CVD is multifactorial and likely includes genetic and lifestyle factors as well as disease specific and treatment effects (16).”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, methodology): “Psychiatric Association supported by the European Association for the Study of Diabetes and by the ESC.(444)”
Inequalities in healthcare provision for people with severe mental illness (2010, background): “For instance, the European Psychiatric Association has recently issued a position statement on cardiovascular disease and diabetes management that sets out standards for monitoring body weight, blood lipids, blood glucose and smoking status on a regular basis (de Hert et al., 2009).”
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021, background): “Psychiatric comorbidities, such as anorexia nervosa and schizophrenia, require close collaboration between the mental health specialist and diabetes care team [207, 208].”
Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis (2016, background): “Thus, considering the observed increased T2DM risks, screening for and trying to minimize risk factors (including adverse lifestyle factors and specific antipsychotic medication choice) should be a key priority in the multidisciplinary treatment of people with SMI (36-39).”
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis (2010, background): “…for CVD such as obesity, smoking, diabetes, hypertension and dyslipidemia are more common in patients with schizophrenia than in the general population (Fleischhacker et al., 2008), and, in addition, antipsychotic medication can induce weight gain or worsen CVD risk factors (De Hert et al., 2009).”
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (2012, background): “…jointly by the European Psychiatric Association together with the European Society of Cardiology and the European Association for the Study of Diabetes included an algorithm for the risk management of cardiovascular disease and diabetes in patients with severe mental illness (De Hert et al. 2009).”
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs (2012, background): “In general, the risk of developing the metabolic syndrome is greatest with clozapine, olanzapine and chlorpromazine; quetiapine confers a moderate increase in risk, whereas risperidone, paliperidone, amisulpride and sertindole are associated with a mild increase in risk, and aripiprazole and ziprasi”
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. (2019, neutral): “189 This is a positive example of considering physical health outcomes for people with severe mental illness.”
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis (2015, background): “Thus, screening for and trying to minimize risk factors (including adverse lifestyle factors and antipsychotic medication choice and use) should be a key priority in the multidisciplinary treatment of people with SMI (46-49).”